drugset / Trial / NCT03360448

AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure

NCT03360448 ↗

Phase 3 Withdrawn Renova Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the safety and efficacy of an intracoronary injection of adenovirus 5 encoding human adenylyl cyclase 6 (RT-100) in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) in a Phase 3 clinical trial.

Timeline

Start
2019-06
Primary completion
2020-06
Completion
2023-06

Outcome

Outcome not reported

Stopped (Business): “Clinical development plans and strategy for RT-100 being re-evaluated”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad5.hAC6 Unknown — Other

Indications